Johnson & Johnson Files For U.S. FDA Approval Of Darzalex Faspro-Based Quadruplet Regimen For Newly Diagnosed Multiple Myeloma Patients For Whom Transplant Is Not Planned
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson has filed for FDA approval of a new treatment regimen for newly diagnosed multiple myeloma patients who are not planning a transplant. The regimen, based on the CEPHEUS study, could become a standard of care.
September 30, 2024 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a new treatment regimen for multiple myeloma, which could become a standard of care.
The filing for FDA approval of a new treatment regimen indicates potential growth in Johnson & Johnson's oncology portfolio. If approved, it could lead to increased sales and market share in the multiple myeloma treatment space.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100